Mode
Text Size
Log in / Sign up
Phase 3 Completed N=501 Randomized Quadruple-blind Treatment

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

Heart Arrest
Source: ClinicalTrials.gov NCT03640949 ↗
Enrolled (actual)
501
Serious AEs
0.0%
Results posted
Jan 2022
Primary outcomePrimary: Number of Participants With Return of Spontaneous Circulation — 100; 86 participants
◆ Published Evidence
Highly cited
127citations · ~25 / year
Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
JAMA · 2021 · Open access · Likely link

Summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

Linked Publications (2)

  • Effect of Vasopressin and Methylprednisolone vs Placebo on Return of Spontaneous Circulation in Patients With In-Hospital Cardiac Arrest: A Randomized Clinical Trial.
    JAMA · 2021 · 127 citations · Open access · Likely link
  • Vasopressin and methylprednisolone for in-hospital cardiac arrest - Protocol for a randomized, double-blind, placebo-controlled trial.
    Resuscitation plus · 2021 · 7 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Return of Spontaneous Circulation
100; 86
SECONDARY
Number of Participants That Survived 30 Days
23; 31
SECONDARY
Number of Participants With a Favorable Neurological Outcome at 30 Days
18; 20

Eligibility Criteria

Inclusion Criteria

  • In-hospital cardiac arrest
  • Age ≥ 18 years
  • Received at least one dose of adrenaline during cardiopulmonary resuscitation

Exclusion Criteria

  • Clearly documented "do-not-resuscitate" order prior to the cardiac arrest
  • Prior enrollment in the trial
  • Invasive mechanical circulatory support at the time of the cardiac arrest
  • Known or suspected pregnancy at the time of the cardiac arrest
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03640949) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search